Lixte Biotechnology (OTCMKTS:LIXT) Shares Down 5.3%
Lixte Biotechnology Holdings Inc (OTCMKTS:LIXT) traded down 5.3% during mid-day trading on Tuesday . The stock traded as low as $0.90 and last traded at $0.90, 1,700 shares traded hands during trading. A decline of 56% from the average session volume of 3,831 shares. The stock had previously closed at $0.95.
The stock’s fifty day moving average is $1.05 and its 200 day moving average is $1.08.
About Lixte Biotechnology (OTCMKTS:LIXT)
Lixte Biotechnology Holdings, Inc operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primary focuses on developing various treatments for human cancers and other non-malignant diseases, including vascular diseases, such as heart attacks and strokes, and diabetes, as well as genetic diseases comprising Gaucher's disease; and depression and post-traumatic stress syndrome.
Receive News & Ratings for Lixte Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lixte Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.